| Stereochemistry | ACHIRAL |
| Molecular Formula | C35H34ClN7O3S2 |
| Molecular Weight | 700.273 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=NN(C(NC(=O)NCC2=CC=CC=C2SC3=CN4C(C=C3)=NN=C4C5=CC=CC=C5SCCO)=C1)C6=CC=C(O)C(Cl)=C6
InChI
InChIKey=VGEXRDWWPSGZDH-UHFFFAOYSA-N
InChI=1S/C35H34ClN7O3S2/c1-35(2,3)30-19-32(43(41-30)23-12-14-27(45)26(36)18-23)38-34(46)37-20-22-8-4-6-10-28(22)48-24-13-15-31-39-40-33(42(31)21-24)25-9-5-7-11-29(25)47-17-16-44/h4-15,18-19,21,44-45H,16-17,20H2,1-3H3,(H2,37,38,46)
| Molecular Formula | C35H34ClN7O3S2 |
| Molecular Weight | 700.273 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
PF-03715455 is a potent p38 inhibitor, showing some selectivity for p38-alpha over p38-beta. PF-03715455 inhibited IL-6, MCP-1, MIP1β, CC16 and CRP levels in plasma of healthy subjects. PF-03715455 was optimized for delivery by inhalation. PF-03715455 substantially reduced tobacco-smoke--induced lung neutrophilia and inflammatory damage to the lungs. PF-03715455 had been in phase II clinical trial for the treatment of asthma and phase I clinical trial for the treatment of chronic obstructive pulmonary disease. However, these investigations were discontinued.
